Pharmacovigilance of Herbal Medicines: Current State and Future Directions

1.

De Smet PAGM. Health risks of herbal remedies. Drug Saf 1995; 13: 81–93PubMedCrossRef

2.

De Smet PAGM. Health risks of herbal remedies: an update. Clin Pharmacol Ther 2004; 76: 1–17PubMedCrossRef

3.

Arlt VM, Stiborova M, Schmeiser HH. Aristolochic acid as a probable human cancer hazard in herbal remedies. Mutagenesis 2002; 17: 265–77PubMedCrossRef

4.

Fu PP, Xia Q, Lin G, et al. Pyrrolizidine alkaloids: genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab Rev 2004; 36: 1–55PubMedCrossRef

5.

Rousseaux CG, Schachter H. Regulatory issues concerning the safety, efficacy and quality of herbal remedies. Birth Defects Research (Part B) 2003; 68: 505–10CrossRef

6.

Marcus DM, Snodgrass WR. Do no harm: avoidance of herbal medicines during pregnancy. Obstet Gynecol 2005; 105(5 Pt 1): 1119–22PubMedCrossRef

7.

Nordeng H, Havnen GC. Use of herbal drugs in pregnancy: a survey among 400 Norwegian women. Pharmacoepidemiol Drug Saf 2004; 13(6): 371–80PubMedCrossRef

8.

Gibson PS, Prowrie R, Star J. Herbal and alternative medicine use: a cross sectional survey. Obstet Gynecol 2001; 97(4 Suppl. 1): S44

9.

Tsui B, Dennehy CE, Tsourounis C. A survey of dietary supplement use during pregnancy at an academic medical center. Am J Obstet Gynecol 2001; 185: 433–7PubMedCrossRef

10.

Tiran D. The use of herbs by pregnant and childbearing women: a risk-benefit assessment. Complement Ther Nurs Midwifery 2003; 9(4): 176–81PubMedCrossRef

11.

Borrelli F, Capasso R, Aviello G, et al. Effectiveness and safety of ginger in the treatment of pregnancy-induced nausea and vomiting. Obstet Gynecol 2005; 105: 849–56PubMedCrossRef

12.

Allkin R, Sampaio E. Collaboration and communication in the ‘caatinga’ of Brazil [online]. 2000. Available from URL: http://www.new-agri.co.uk/00-2/develop/dev04.html

13.

The international plant name index [online]. 2004. Available from URL: http://www.ipni.org

14.

Species [online]. 2000. Available from URL: http://www.sp2000.org

15.

Missouri Botanical Gardens. The Tropicos system [online]. Available from URL: http://mobot.mobot.org/W3T/Search/vast.html

16.

The world checklist of monocotyledons [online]. The Board of Trustees of the Royal Botanic Gardens, Kew, 2005. Available from URL: http://www.kew.org/monocotChecklist

17.

iPlants. The world’s plants online. Available from URL: http://www.iplants.org

18.

CMPACC [online]. Available from URL: http://www.rbgkew.org.uk/scihort/ecbot/ecbot-cmpac.html

19.

5th International ESCOP symposium, London: Professor Ralph Edwards, WHO, 1998

20.

European Commision. 7th Amendment to EU Cosmetics Directive [online]. 2003. Available from: URL: http://europa.eu.int/eur-lex/en/dat/2003/l_066/l_06620030311e0260035.pdf

21.

Scientific Committee on Consumer Products. Opinion on tea tree oil 2004. European Commission report SCCP/0843/04

22.

International Fragrance Association. Guidelines [online]. Available from URL: http://www.ifraorg.org/GuideLines.asp

23.

Maddocks-Jennings W. Critical incident: idiosyncratic allergic reactions to essential oils. Complement Ther Nurs Midwifery 2004; 10(1): 58–60CrossRef

24.

Frosch PJ, Johansen JD, Menne T, et al. Further important sensitizers in patients sensitive to fragrances: II. Reactivity to essential oils. Contact Dermatitis 2002; 47(5): 279–87PubMedCrossRef

25.

Howie J. Developing an adverse events reporting system for skin reactions to aromatherapy: a pilot study. FACT 2004; 9Suppl. 1: 16–7

26.

Mahady GB. Global harmonization of herbal health claims. J Nutr 2001; 131(3s): 1120S–3SPubMed

27.

Barnes J. Pharmacovigilance of herbal medicines: a UK perspective. Drug Saf 2003; 26(12): 829–51PubMedCrossRef

28.

Hartigan-Go K. Developing a pharmacovigilance system in the Philippines, a country of diverse culture and strong traditional medicine background. Toxicology 2002; 103-7: 181–2

29.

Barnes J, Mills SY, Abbot NC, et al. Different standards for reporting ADR’s to herbal remedies and conventional OTC medicines: face-to-face interviews with 515 users of herbal remedies. Br J Clin Pharmacol 1998; 45: 496–500PubMedCrossRef

30.

Available from URL: http://www.escop.com/phytonet.htm

31.

Fucik H, Backlund A, Farah M. Building a computerized herbal substance register for implementation and use in the WHO international drug monitoring programme. Drug Inf J 2002; 36: 839–54CrossRef

32.

The Uppsala Monitoring Centre. Guidelines for herbal ATC classification. Uppsala: The UMC, 2004

33.

Fayyad UM, Piatetsky-Shapiro G, Smyth P. From data mining to knowledge discovery: an overview. In: Fayyad UM, Piatetsky-Shapiro G, Smyth P, et al., editors. Advances in knowledge discovery and data mining. Menlo Park (CA): AAAI Press/The MIT Press, 1996: 1–34

34.

Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54(4): 315–21PubMedCrossRef

35.

Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology 1996; 46(6): 1775–6PubMedCrossRef

36.

Hauser D, Gayowski T, Singh N. Bleeding complications precipitated by unrecognized Gingko biloba use after liver transplantation. Transpl Int 2002; 15(7): 377–9PubMedCrossRef

37.

Engelberg D, McCutcheon A, Wiseman S. A case of ginseng-induced mania. J Clin Psychopharmacol 2001; 21(5): 535–7PubMedCrossRef

38.

Vazquez I, Aguera-Ortiz LF. Herbal products and serious side effects: a case of ginseng-induced manic episode. Acta Psychiatr Scand 2002; 105(1): 76–7; discussion 77-8PubMed

39.

Wood L. In: Pharmacovigilance. Mann R, Andrews E, editors. John Wiley & Sons Ltd, 2002

40.

General practice research database !online]. Available from URL: http://www.GPRD.com [Accessed 2006 Jan 6]

41.

Barnes J. Pharmacovigilance of herbal medicines: a UK perspective. Drug Saf 2003; 26(12): 829–51PubMedCrossRef

42.

Sinclair HK, Bond CM, Hannaford PC. Pharmacovigilance of over-thecounter products based in community pharmacy: a feasible option? Pharmacoepidemiol Drug Saf 1999; 8: 479–91PubMedCrossRef

43.

Layton D, Sinclair HK, Bond CM, et al. Pharmacovigilance of over-the-counter products based in community pharmacy: methodological issues from pilot work conducted in Hampshire and Grampian, UK. Pharmacoepidemiol Drug Saf 2002; 11: 503–13PubMedCrossRef

44.

Reif K, Metzger W. Determination of aflatoxins in medicinal herbs and plant extracts. J Chromatogr A 1995; 692: 131–6CrossRef

45.

Reif K, Schwind B. Development of high performance liquid chromatography - tandem mass spectrometry (HPLC-MS/MS) methods for the screening of mycotoxins in herbal raw materials [poster]. 51st Annual Congress of the Society for Medicinal Plant Research; 2003 Aug 31- Sep 4, Kiel

46.

Kabelitz L. Contamination of herbal drugs in regulations and future developments. Herba Polonica 2003; 49: 89–104

47.

Barnes J, Aggarwal AM. Spontaneous reporting of ADRs associated with herbal medicines: a cross-sectional survey of national pharmacovigilance centres [abstract]. ISoP 2004. Drug Saf 2004; 27(12): 917

48.

Chrystal K, Allan S, Forgeston G, Isaacs R. The use of complementary/alternative medicine by cancer patients in a New Zealand regional treatment centre. NZ Med J 2003; 116(1168): 296–304

49.

MacLennan AH, Wilson DH, Taylor AW. The escalating cost and prevalence of alternative medicine. Prev Med. 2002; 35: 166–73PubMedCrossRef

50.

Grymonpre RE, McKechnie M, Briggs C. Community pharmacists’ identification of natural health product/drug interactions in older persons. Int J Pharm Prac 2003; 11: 217–23CrossRef

51.

Brooker SG, Cambie RA, Cooper R.C. New Zealand Medicinal Plants. 2nd Ed. Auckland: Heinemann; 1987

52.

Best E. Maori religion and mythology. Dominion Museum Bulletin, 1924: 10

53.

MacDonald C. Medicines of the Maori. Auckland: Collins; 1973

54.

Mahady GB. Black cohosh (Actaea/Cimicifuga racemosa): review of the clinical data for safety and efficacy in menopausal symptoms. Treat Endocrinol 2005; 4(3): 177–84PubMedCrossRef

55.

Beatty C, Denham A. Review of Practice: preliminary data collection for clinical audit. Eur J Herb Med 1998; 4(2): 32–3.

56.

Greene JG. Constructing a standard climacteric scale. Maturitas 1998; 29: 25–31.PubMedCrossRef

57.

MacLennan AH, Myers SP, Taylor AW. The continuing use of complementary and alternative medicine in South Australia: costs and beliefs in 2004. Med J Aust 2006; 184: 27–31PubMed

58.

Expert committee report: Complementary medicines in the Australian health system 2003 [online]. Available from URL: http://www.tga.gov.au/docs/html/cmreport1.htm [Accessed 6 January 2006]

59.

Mozaffarian V. A dictionary of Iranian plant names. Tehran: Farhang Moaser, 1996: 522

60.

Blumenthal M. et al. The complete German commission E monographs. 1st ed. Austin (TX): American Botanical Council, 1998: 219

61.

Moody JO, Hyland PJ and Bray DH. In vitro evaluation of Enantia chlorantha: constituents and derivatives for antiplasmodial and anticandidal activity. Pharm Pharmacol Lett 1995; 2: 80–2

62.

Carpenter L, Prazuck T, Vincent-Ballereau F, et al. Choice of traditional or modern treatment in West Burkina Fasso. World Health Forum, 1995

63.

Sofowora A. Medicinal plants and traditional medicine in Africa. John Wiley and Sons, 1982: 198–202

64.

Wirth DP. The significance of belief and expectancy within the spiritual healing encounter. Soc Sci Med 1995; 41(2) 249–60PubMedCrossRef

65.

Bensky D, Clavey S, Stoger E. Chinese herbal medicine Materia Medica. 3rd ed. Seattle Eastland Press Inc, 2004

66.

But PP-Y, Tomlinson B, Lee KL. Hepatitis related to the Chinese medicine Shou-wu-pian manufactured from Polygonum multiflorum. Vet Human Toxicol 1996; 38(4): 280–1

67.

Panis B, Wong D, Hooymans P, et al. Recurrent toxic hepatitis in a Caucasian girl related to the use of Shou-Wu-Pian, a Chinese herbal preparation. J Pediatr Gastroenterol Nutr 2005; 41(2): 256–8PubMedCrossRef

68.

Barnes J, Teng L, Shaw D. TCM: balancing choice and risk? Pharm J 2004; 273: 342

69.

Barnes J. Pharmacovigilance of herbal medicines: a UK perspective. Drug Saf 2003; 26: 829–51PubMedCrossRef

70.

Barnes J, Teng L, Shaw D. TCM: balancing choice and risk? Pharm J 2004; 273: 342.

71.

Vanherweghem JL, Depierreux M, Tielemans C, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993; 13(341): 387–91.CrossRef

72.

Stiborova M, Fernando RC, Schmeiser HH, et al. Characterization of DNA adducts formed by aristolochic acid in target organ of rat by 32P-postlabelling analysis using different chromatographic procedures. Carcinogenesis 1994; 15: 1187–92.PubMedCrossRef

73.

Tanaka A, Nishida R, Maeda K, et al. Chinese herb nephropathy in Japan presents adult-onset Fanconi syndrome: could different components of aristolochic acid cause a different type of Chinese herb nephropathy? J Clin Nephrol 2000; 53: 301–6.

Springer Medizin

Pharmacovigilance of Herbal Medicines: Current State and Future Directions

London, UK, 26–28 April, 2006

Excerpt

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2006

Long-Term Treatment with Atypical Antipsychotics and the Risk of Weight Gain

Safety of Drug Therapies Used for Weight Loss and Treatment of Obesity

Thalidomide Use in the US

Influence of Pharmacists’ Attitudes on Adverse Drug Reaction Reporting